Gilead Sciences Inc
NASDAQ: GILD
$96.57
-$1.34 (-1.4%)
Closing Price on November 8, 2024
GILD Articles
Here are a few big biopharma names on which Wall Street is growing more bearish.
Published:
Monday afternoon's top analyst upgrades and downgrades included American Electric, BP, Dollar Tree, Gilead, Lockheed Martin and more.
Published:
Thursday's premarket winners and losers included Meta Platforms, PayPal, Spotify, T-Mobile and Twitter.
Published:
Friday afternoon's top analyst upgrades and downgrades included Apple, Gilead, Goldman Sachs, Kroger, Raymond James, and more.
Published:
Friday's top analyst upgrades and downgrades included CrowdStrike, Exxon Mobil, Ford, Gilead Sciences, Goldman Sachs, Honeywell International, Lowe’s, Lyft, Progressive and Zscaler.
Published:
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy at top...
Published:
Monday afternoon's analyst upgrades and downgrades included American Airlines, Biogen, Citigroup, EA, Gilead, Meta, Micron, Zscaler and more.
Published:
24/7 Wall St. screened the Jefferies Franchise Picks, looking for the companies that pay solid dividends and also are strong plays in a very inflationary world. These stocks make good sense for...
Published:
Friday's top analyst upgrades and downgrades included Arista Networks, DataDog, FedEx, Fiserv, Gilead Sciences, Global Payments, Nvidia, Oatly, Pfizer, Target, TJX Companies and Victoria’s Secret.
Published:
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate...
Published:
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost...
Published:
Wednesday's top analyst upgrades and downgrades included Anheuser-Busch, Bank of New York Mellon, Gilead Sciences, Micron Technology, Mosaic, Netflix, Philip Morris International, Synchrony...
Published:
While not suited for conservative income investors, these two top biotech stocks could have huge total return potential and offer investors with a touch more risk tolerance some very tempting entry...
Published:
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Amazon.com, Edwards Lifesciences, Gilead Sciences, Mastercard and Pinterest.
Published:
These four Jefferies stock picks in the health care space offer outstanding upside potential for investors long term and look like very solid ideas for the rest of 2021, especially with an overbought...
Published: